2 Xideas Ag Vertex Pharmaceuticals Inc Transaction History

2 Xideas Ag

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $1.33 Million - $1.59 Million	-3,870 Reduced 11.07%	31,089 $12.6 Million
Q3 2023 Nov 07, 2023	SELL	$338.18 - $362.46 $709,501 - $760,441	-2,098 Reduced 5.66%	34,959 $12.2 Million
Q2 2023 Aug 10, 2023	BUY	$314.42 - $351.91 $181,105 - $202,700	576 Added 1.58%	37,057 $13 Million
Q1 2023 May 11, 2023	BUY	$283.23 - $323.1 $714,022 - $814,535	2,521 Added 7.42%	36,481 $11.5 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $507,509 - $570,948	1,776 Added 5.52%	33,960 $9.81 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $4.77 Million - $5.32 Million	-17,424 Reduced 35.12%	32,184 $9.32 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $5.21 Million - $6.48 Million	-22,157 Reduced 30.87%	49,608 $14 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $1.87 Million - $2.21 Million	-8,461 Reduced 10.55%	71,765 $18.7 Million
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $4.14 Million - $5.22 Million	23,363 Added 41.09%	80,226 $17.6 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $2.3 Million - $2.58 Million	12,692 Added 28.73%	56,863 $10.3 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $1.52 Million - $1.79 Million	8,097 Added 22.45%	44,171 $8.91 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $1.08 Million - $1.26 Million	5,210 Added 16.88%	36,074 $7.75 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $6.39 Million - $8.52 Million	30,864 New	30,864 $7.29 Million

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of 2 Xideas Ag, based on Form 13F filings with the SEC.

Stay updated on 2 Xideas Ag with notifications on news.